Table 2.
ALK and TRK inhibitors under investigation for NB
| Drug name | Company | Targets | Status |
|---|---|---|---|
| Crizotinib (Xalkori®) | Pfizer, Inc. | ALK (first generation), MET, ROS1 | Approved |
| • ALK- and ROS1-rearranged NSCLC | |||
| Ceritinib (Zykadia®) | Novartis International AG | ALK (second generation), IGF-1R143 | Approved |
| • ALK-positive NSCLC | |||
| Alectinib (Alecensa®) | Chugai Pharmaceutical Co. | ALK (second generation), RET | Approved |
| • ALK-positive NSCLC | |||
| Lorlatinib | Pfizer, Inc. | ALK (third generation), ROS1 | Clinical |
| • PF-6463922 | • Phase III | ||
| CEP-751 | Cephalon, Inc. | TRKA/B/C, PDGFR, EGFR, PKC | Preclinical |
| • KT-6587 | • No longer under investigation | ||
| AZ64 | AstraZeneca, Inc. | TRKA/B/C | Preclinical |
| • No longer under investigation | |||
| GNF-4256 | Genomics Institute of the Novartis Research Foundation | TRKA/B/C | Preclinical |
| • No longer under investigation | |||
| Lestaurtinib | Teva Pharmaceutical | TRKA/B/C, JAK2, Flt3 | Clinical |
| • CEP-701 | Industries Ltd | • No longer under investigation | |
| Larotrectinib | Loxo Oncology, Inc. | TRKA/B/C | Clinical |
| • LOXO-101, ARRY-470 | • Phase II | ||
| Entrectinib | Ignyta, Inc. | TRKA/B/C, ALK, ROS1 | Clinical |
| • RXDX-101, NMS-E628, NMS-01191372 | • Phase II |
Note: Drugs approved or those that remain under investigation are highlighted in bold.
Abbreviation: NB, neuroblastoma.